Clinical trials: Malignant Tumor Liver
Colorectal Cancer, Coffee
COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
This is research study is assessing the effects of 6-g daily use of freeze-dried instant coffee on liver fat and fibrosis and the gut microbiome and metabolome in patients who have completed routine treatment (including surgery…
- Conditions
- Colorectal Cancer, Coffee, Gastrointestinal Microbiome, Stenosis
- Trial name
- COMMENCER (NCT05692024)
- Testing
- Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
This phase I trial is studying the side effects and best dose of oxaliplatin when given together with irinotecan in treating young patients with refractory solid tumors or lymphomas.
- Conditions
- Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis
- Trial name
- NCT00101270
- Testing
- irinotecan hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Hepatoblastoma, Hepatocellular Carcinoma
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells.
- Conditions
- Hepatoblastoma, Hepatocellular Carcinoma, Wilms Tumor, Malignant Rhabdoid Tumor
- Trial name
- NCT06198296
- Testing
- 21.15.GPC3-CAR T cells
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Baylor College of Medicine
Hepatocellular Carcinoma
An Individualized Anti-Cancer Vaccine Study in Patients With HCC
The purpose of this study is to determine the safety and the immunological, radiological, and pathological response of the personalized anti-cancer vaccine AlloVax(TM) in patients with refractory Hepatocellular Carcinoma (HCC)…
- Trial name
- NCT01995227
- Testing
- AlloVax, CRCL, AlloStim
- Where
- Israel
- Sponsor
- Mirror Biologics, Inc.
Solid Tumor, Lymphoma
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
This is a single arm Phase 2 study of the combination of adenoviral p53 (Ad-p53) gene therapy administered intra-tumorally with approved immune checkpoint inhibitors in patients with recurrent or metastatic cancers.
- Trial name
- NCT03544723
- Testing
- Ad-p53
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- MultiVir, Inc.
Hepatocellular Cancer, Metastatic Liver Cancer
Prospective Tumor Response Evaluation
The purpose of this study is to determine if MRI imaging can detect genetic, proteomic, and metabolomic characteristics of liver tumors.
- Trial name
- Liver (NCT02787954)
- Testing
- TACE, Y-90, MWA
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The University of Texas Health Science Center, Houston
Neoplasm Metastasis
Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden
The purpose of this study is to determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.
- Trial name
- OXi4503 (NCT00960557)
- Testing
- Combretastatin A1 Diphosphate (OXi4503)
- Where
- 4 sites in Australia
- Volunteers
- 16 people
- Sponsor
- Mateon Therapeutics
Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors
CapTemY90 for Grade 2/3 NET Liver Metastases
This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety…
- Trial name
- CapTemY90 (NCT04339036)
- Testing
- Capecitabine Oral Product, Temozolomide Oral Product, transarterial radioembolization
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Hepatocellular Carcinoma (HCC)
Dietary Intervention and Gut Microbiota in Hepatocellular Carcinoma (HCC)
This prospective, randomized controlled trial investigates the efficacy of a targeted dietary intervention in patients with hepatocellular carcinoma (HCC).
- Trial name
- NCT07143955
- Testing
- Structured Dietary Intervention, Routine Dietary Care
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Hospital of Hebei Medical University
Carcinoma, Hepatocellular
Cytotoxicity Induced by Tumor Lysate Pulsed Dendritic Cells Against Autologous Hepatocellular Carcinoma Cells
Hepatoma ranks the first on the cancer mortality list in Taiwan, and there are currently no other effective treatment options for advanced HCC.
- Trial name
- NCT00327496
- Testing
- DC vaccine
- Volunteers
- 10 people
- Sponsor
- Mackay Memorial Hospital
Head and Neck Cancer, Islet Cell Tumor
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Conditions
- Head and Neck Cancer, Islet Cell Tumor, Metastatic Cancer, Pheochromocytoma
- Trial name
- NCT00466856
- Testing
- octreotide acetate, yttrium Y 90 resin microspheres
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Hepatocellular Carcinoma, Hepatocellular Cancer
Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion
The recent global IMbrave150 study evaluated the combination of atezolizumab and bevacizumab versus sorafenib in 501 patients with advanced or metastatic Hepatocellular Carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Stage IV
- Trial name
- ALERT-HCC (NCT05992220)
- Testing
- Atezolizumab plus bevacizumab, combined EBRT to vascular invasion, Atezolizumab plus bevacizumab
- Where
- South Korea
- Volunteers
- 138 people
- Sponsor
- Asan Medical Center
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Neoplasms, Liver Metastases
A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases
Background: A protein called HIF is believed to be involved both in forming cancers and helping them to grow after they are formed.
- Trial name
- NCT01120288
- Testing
- EZN-2968
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer, Gastric Adenocarcinoma
Stomach Cancer Exosome-based Detection
Gastric cancer continues to have a poor prognosis primarily due to the inability to detect it in its early stages. This study will develop and validate a blood assay to facilitate the non-invasive detection of gastric cancer.
- Conditions
- Gastric Cancer, Gastric Adenocarcinoma, Gastric Cancer Stage, Gastric Neoplasm
- Trial name
- DESTINEX (NCT06342427)
- Testing
- DESTINEX
- Where
- 3 sites in United States, Japan
- Volunteers
- 809 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction
RATIONALE: Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00540982
- Testing
- indocyanine green, lidocaine, vinorelbine ditartrate
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- City of Hope Medical Center
Carcinoma, Hepatocellular, Colorectal Neoplasms
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
This study will follow-up immune cell populations, secreted factors and released nanovesicles in the blood before, during and after high dose radiation therapy which should give new information of the efficacy of the…
- Conditions
- Carcinoma, Hepatocellular, Colorectal Neoplasms, Melanoma, Kidney Neoplasms
- Trial name
- NCT02439008
- Testing
- Blood samples collection before radiotherapy, Blood samples collection during radiotherapy, Blood samples collection after radiotherapy
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Centre Oscar Lambret
Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to…
- Conditions
- Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06084481
- Testing
- ABBV-400, Itraconazole (ITZ), Bevacizumab
- Where
- 54 sites in United States, Australia and 6 more
- Volunteers
- 325 people
- Sponsor
- AbbVie
Cirrhosis, Hepatitis B Infection
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
This phase I trial studies the side effects and the best dose of navitoclax when given together with sorafenib tosylate in treating patients with solid tumors that have returned (relapsed) or do not respond to treatment…
- Conditions
- Cirrhosis, Hepatitis B Infection, Hepatitis C Infection, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT02143401
- Testing
- Laboratory Biomarker Analysis, Navitoclax, Pharmacological Study
- Where
- 10 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma
Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors
This phase II trial studies the side effects and how well imetelstat sodium works in treating younger patients with relapsed or refractory solid tumors.
- Conditions
- Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Rhabdomyosarcoma
- Trial name
- NCT02011126
- Testing
- Imetelstat Sodium, Laboratory Biomarker Analysis
- Sponsor
- Children's Oncology Group